Tech Company M&A Transactions
Afferent Pharmaceuticals Acquisition
Afferent Pharmaceuticals was acquired by Merck. The transaction was announced on 6/10/2016. Financial terms set the valuation at $1.3 billion.
Transaction Overview
Company Name
Acquired By
Announced On
6/10/2016
Transaction Type
M&A
Amount
$1,250,000,000
M&A Terms
Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of Afferent in exchange for an upfront payment of $500 million in cash. Also, Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with the attainment of certain clinical development and commercial milestones for multiple indications and candidates, including AF-219
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2755 Campus Dr. 100
San Mateo, CA 94403
USA
San Mateo, CA 94403
USA
Phone
Website
Email Address
Not Recorded
Overview
A leader in the development of novel, selective small molecules that target the P2X3 purinergic receptor, for the treatment of a range of debilitating symptoms and sensory disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kathleen Glaub
Chief Medical Officer
Michael Kitt
Chief Scientific Officer
Anthony Ford
VP - Operations
Peter Butera
Browse more venture capital transactions:
Prev: 6/10/2016: Accelergy venture capital transaction
Next: 6/10/2016: Sostena venture capital transaction
Share this article
News on VC Transactions
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs